The Biotechnology Innovation Organization submitted a formal statement to the House Ways & Means Trade Subcommittee urging targeted federal actions to sustain U.S. biotech leadership. BIO recommended restoring and expanding R&D tax credits, creating a Federal Angel Investor Tax Credit, and offering incentives for reshoring contract manufacturing and pilot‑scale facilities in cell, gene, and mRNA modalities. The group argued such steps would secure supply chains, boost domestic manufacturing capacity, and accelerate translational pipelines — recommendations detailed in BIO’s Jan. 13 testimony to Congress.